Supernus Pharmaceuticals Management
Management criteria checks 2/4
Supernus Pharmaceuticals' CEO is Jack Khattar, appointed in Jan 2005, has a tenure of 19.92 years. total yearly compensation is $13.28M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 3.53% of the company’s shares, worth $69.04M. The average tenure of the management team and the board of directors is 9.7 years and 12.3 years respectively.
Key information
Jack Khattar
Chief executive officer
US$13.3m
Total compensation
| CEO salary percentage | 7.3% |
| CEO tenure | 19.9yrs |
| CEO ownership | 3.5% |
| Management average tenure | 9.7yrs |
| Board average tenure | 12.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$60m |
| Jun 30 2024 | n/a | n/a | US$5m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$13m | US$963k | US$1m |
| Sep 30 2023 | n/a | n/a | US$26m |
| Jun 30 2023 | n/a | n/a | US$43m |
| Mar 31 2023 | n/a | n/a | US$52m |
| Dec 31 2022 | US$10m | US$914k | US$61m |
| Sep 30 2022 | n/a | n/a | US$38m |
| Jun 30 2022 | n/a | n/a | US$57m |
| Mar 31 2022 | n/a | n/a | US$73m |
| Dec 31 2021 | US$8m | US$870k | US$53m |
| Sep 30 2021 | n/a | n/a | US$82m |
| Jun 30 2021 | n/a | n/a | US$100m |
| Mar 31 2021 | n/a | n/a | US$111m |
| Dec 31 2020 | US$7m | US$836k | US$127m |
| Sep 30 2020 | n/a | n/a | US$129m |
| Jun 30 2020 | n/a | n/a | US$118m |
| Mar 31 2020 | n/a | n/a | US$116m |
| Dec 31 2019 | US$8m | US$812k | US$113m |
| Sep 30 2019 | n/a | n/a | US$106m |
| Jun 30 2019 | n/a | n/a | US$105m |
| Mar 31 2019 | n/a | n/a | US$103m |
| Dec 31 2018 | US$7m | US$724k | US$111m |
| Sep 30 2018 | n/a | n/a | US$99m |
| Jun 30 2018 | n/a | n/a | US$87m |
| Mar 31 2018 | n/a | n/a | US$73m |
| Dec 31 2017 | US$6m | US$614k | US$57m |
Compensation vs Market: Jack's total compensation ($USD13.28M) is above average for companies of similar size in the UK market ($USD2.35M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.
CEO
Jack Khattar (63 yo)
19.9yrs
Tenure
US$13,278,093
Compensation
Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 19.9yrs | US$13.28m | 3.53% $ 69.0m | |
| Senior VP & CFO | 3.3yrs | US$2.38m | 0.013% $ 254.7k | |
| Chief Scientific Officer & Senior VP of Intellectual Property | 12.8yrs | US$1.47m | 0.018% $ 343.0k | |
| Senior Vice President of Quality | 4.9yrs | US$1.79m | 0.015% $ 290.5k | |
| Senior VP of Research & Development and Chief Medical Officer | 4.8yrs | US$1.59m | 0.0084% $ 164.3k | |
| Compliance Officer | 12.9yrs | no data | no data | |
| Senior Vice President of Marketing | 9.9yrs | no data | no data | |
| Senior Vice President of Sales | 9.9yrs | no data | no data | |
| Senior Vice President of Corporate Development | 9.4yrs | no data | no data | |
| Senior Vice President of Supply Chain | 3.6yrs | no data | no data |
9.7yrs
Average Tenure
63yo
Average Age
Experienced Management: 0LB2's management team is seasoned and experienced (9.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 19.9yrs | US$13.28m | 3.53% $ 69.0m | |
| Independent Chairman of the Board | 19.9yrs | US$407.02k | 0.24% $ 4.6m | |
| Independent Director | 9.8yrs | US$378.52k | 0.024% $ 471.7k | |
| Independent Director | 6.5yrs | US$376.02k | 0.031% $ 609.4k | |
| Independent Director | 14.9yrs | US$385.02k | 0.051% $ 1.0m | |
| Director | less than a year | US$514.39k | no data |
12.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 0LB2's board of directors are seasoned and experienced ( 12.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:30 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Supernus Pharmaceuticals, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| David Buck | B. Riley Securities, Inc. |
| John Tanner | Cantor Fitzgerald & Co. |